ArticleClinical and experimental pediatrics2025
Hyperhomocysteinemia in pediatric β-thalassemia: links to vitamin cofactor deficiencies and oxidative stress.
Article in Clinical and experimental pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- β-Thalassemia Minor and Pregnancy Outcomes: Pathophysiology, Clinical Implications, and Management.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHomocysteine metabolism is crucial to maintaining vascular and metabolic homeostasis, yet its dysregulation in pediatric β-thalassemia major (β-TM) remains poorly understood. PURPOSE: This study investigated the prevalence and determinants of hyperhomocysteinemia in pediatric β-TM with a focus on vitamin B9 (folate), B12, and B6 deficiencies, oxidative stress marker levels, and the impact of splenectomy.
methodsA cross-sectional study was conducted of 92 pediatric β-TM patients. Levels of plasma homocysteine, vitamins B9, B12, and B6, and oxidative stress marker (protein carbonyls, thiols, nitrotyrosine, and nitric oxide metabolites) levels were measured. The patients were grouped based on their splenectomy status. The MTHFR C677T polymorphism was genotyped in a subset of patients (n=39). The statistical analyses included t tests, analysis of variance, Pearson's correlation, and multivariate regression.
resultsOverall, 93% of patients had hyperhomocysteinemia (≥15 μM), with the values of 50% exceeding 30 μM. Homocysteine levels were negatively correlated with folate levels (r=-0.22, P=0.03) and weakly correlated with B12 levels (r=-0.18, P=0.08). Vitamin B6 levels were not significantly associated with homocysteine levels. Post-splenectomy, patients had significantly higher homocysteine levels (43.3 μM vs. 32.3 μM, P=0.002) but lower nitrotyrosine levels (P=0.035), suggesting reduced nitrative stress. The MTHFR C677T genotype did not significantly influence homocysteine levels in our cohort.
conclusionHyperhomocysteinemia is prevalent in pediatric β-TM, driven primarily by severe folate and B12 deficiencies. Splenectomy exacerbates hyperhomocysteinemia but reduces nitrative stress, indicating complex metabolic shifts postsplenectomy. These findings highlight the need for routine homocysteine monitoring and targeted vitamin supplementation to mitigate the potential vascular risks of pediatric thalassemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.